Next Article in Journal
Indole-Based Hydrazones Containing A Sulfonamide Moiety as Selective Inhibitors of Tumor-Associated Human Carbonic Anhydrase Isoforms IX and XII
Next Article in Special Issue
Hair Growth Promoting Effect of 4HGF Encapsulated with PGA Nanoparticles (PGA-4HGF) by β-Catenin Activation and Its Related Cell Cycle Molecules
Previous Article in Journal
Interaction of Mycotoxin Alternariol with Serum Albumin
Previous Article in Special Issue
Citrate-Induced p85α–PTEN Complex Formation Causes G2/M Phase Arrest in Human Pharyngeal Squamous Carcinoma Cell Lines
Open AccessReview

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer

1
Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy
2
Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy
3
Units of Oncology, ASL Verbano Cusio Ossola (VCO), Via Fiume, 18, 28922 Verbania, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(9), 2353; https://doi.org/10.3390/ijms20092353
Received: 28 February 2019 / Revised: 15 April 2019 / Accepted: 10 May 2019 / Published: 12 May 2019
(This article belongs to the Special Issue Cyclin-Dependent Kinases in Health and Diseases)
Endometrial Cancer (EC) is an important cause of death in women worldwide. Despite early diagnosis and optimal treatment of localized disease, relapsed patients have few therapeutic options because after first line therapy, currently no standard of care exists. On the basis of endocrine positivity of most endometrioid ECs, Endocrine Therapy (ET) is a reasonable and widely accepted option. Better knowledge of molecular mechanisms involved in cancer highlighted the deregulated activity of Cyclin-Dependent Kinases (CDKs) in the cell cycle as a hallmark of carcinogenesis supporting the development of a new class of drugs: CDK inhibitors (CDKis). The aim of this review is to give an overview on CDKis preclinical, early clinical activity and future development in EC. Use of CDKis has a strong preclinical rationale but we have poor clinical data. Similar to breast cancer, most ongoing trials are investigating synergistic associations between CDKis and ET. These trials will probably help in defining the best clinical setting of CDKis in ECs, which are the best partner drugs, and how to manage CDKis toxicities with a focus on potential biomarkers of response. View Full-Text
Keywords: cyclin-dependent kinase inhibitors; endometrial cancer; cyclin-dependent kinases cyclin-dependent kinase inhibitors; endometrial cancer; cyclin-dependent kinases
Show Figures

Figure 1

MDPI and ACS Style

Giannone, G.; Tuninetti, V.; Ghisoni, E.; Genta, S.; Scotto, G.; Mittica, G.; Valabrega, G. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. Int. J. Mol. Sci. 2019, 20, 2353.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop